Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00927121
Other study ID # 09/1525
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received June 22, 2009
Last updated April 18, 2012

Study information

Verified date April 2012
Source ANM Adaptive Neuromodulation GmbH
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

There are many treatments for chronic tinnitus that have been claimed, with varying degrees of statistical reliability. None of those treatments can eradicate the tinnitus completely. Some therapies can reduce the tinnitus symptoms (loudness, annoyance) up to 30%. Thus there is still a need of new treatments that can reduce considerably the tinnitus symptoms and improve the QOL of subjects.

Trial objectives:

- The aim of this trial is the improvement of the QOL (quality of live) by reducing the Tinnitus- Symptoms of the patient.

- To confirm the efficacy and safety of the coordinated reset technology.

These objectives will be assessed:

- By subjective and objective measurements of the Tinnitus symptoms, loudness and annoyance.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Mentally healthy people

- Chronic tonal Tinnitus

- Older than 18 years

- Signature of the patient informed consent

- No participation in other tinnitus therapy during the clinical investigation

Exclusion Criteria:

- A necessity for hearing aid

- Auditory hallucination

- Symptomatic hearing disorders

- "Morbus Meniere",

- Tinnitus due to temporomandibular joint disorders

- Subjects who can't perceive therapeutic tones

- Brainstem diseases

- Psychiatric disorders

- Objective Tinnitus

- Insufficient treatment of general disorders, anemia, tumor, dialysis, hypertonus ect.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset
The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity. Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation. The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system

Locations

Country Name City State
Germany Research Center Jülich // Institute for Neurosciences and Medicine - Research Center Jülich

Sponsors (1)

Lead Sponsor Collaborator
ANM Adaptive Neuromodulation GmbH

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Tass PA, Adamchic I, Freund HJ, von Stackelberg T, Hauptmann C. Counteracting tinnitus by acoustic coordinated reset neuromodulation. Restor Neurol Neurosci. 2012;30(2):137-59. doi: 10.3233/RNN-2012-110218. — View Citation